HACKENSACK, N.J., June 5, 2013 (GLOBE NEWSWIRE) -- Champions Oncology, Inc. (OTC:CSBR) is pleased to announce the oral presentation of a new paper, "Integrated Genomics and Avatar Mouse Models for Personalized Cancer Treatment", at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting on June 1st in Chicago, IL.
This groundbreaking study combined deep sequencing with mouse avatar testing in 19 patients. The work, a collaborative effort between investigators at the Spanish National Cancer Research Centre, Champions Oncology and Personal Genome Diagnostics, Inc., demonstrated that most patients in the study received clinical benefit from the combination of deep sequencing and mouse avatar testing.
In the study, exome sequencing analysis was used to inform the selection of drugs that were tested in mouse avatar models for 13 patients. The results of the mouse avatar tests were used to guide treatment for these patients. 11 of the 13 patients received clinical benefit from the avatar guided therapy.
"The study results demonstrated the strong predictive power of avatar models as an investigational, personalized tool for therapeutic decision-making and their utility in helping to guide cancer treatment in the clinic," stated Joel Ackerman, CEO of Champions Oncology. "We look forward to further testing this strategy in the coming months in several prospective, clinical validation studies, in line with our goal of developing innovative solutions in personalized oncology."
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through its Personalized Oncology Solutions business.
This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2012 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.
CONTACT: Lauren Kwiecinski The Trout Group 646-378-2934 email@example.comSource:Champions Oncology